The new data supports therapeutic rationale for first-in-class androgen receptor inhibitor.

Results from two Phase 3  pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older.

The findings were presented at the American Academy of Dermatology (AAD) 2022 Annual Meeting in Boston.

The two multicenter, randomized, double-blind pivotal Phase 3 trials enrolled more than 1440 subjects with moderate-to-severe acne vulgaris who received either WINLEVI or placebo for 12 weeks. The primary efficacy endpoints were 1) the proportion of patients achieving "success," defined as an Investigator Global Assessment (IGA) score of 0 ("clear") or 1 ("almost clear"), with at least a 2-point reduction in IGA score from baseline; and 2) absolute change from baseline in non-inflammatory lesion counts (NILC) and inflammatory lesion counts (ILC) at Week 12. Safety was assessed from local skin reactions (LSRs) and treatment-emergent adverse events (TEAEs) through Week 12 (measured at baseline and at Weeks 4, 8, and 12).

In the two studies, 18.8 percent and 20.9 percebt of Winlevi-treated patients achieved success based on IGA at Week 12, compared with 8.7 percent and 6.6 percent of patients receiving placebo (P < 0.01). The mean absolute change from baseline in NILCs at Week 12 was -20.4 and -19.5 for patients treated with Winlevi, versus -13.0 and -10.8 for placebo-treated patients (P ≤ 0.0001). The mean absolute change from baseline in ILCs at Week 12 was -19.3 and -20.1 in the Winlevi groups, compared to -15.4 and -12.6 in the two studies' placebo groups (P < 0.01).

The safety profile of Winlevi was similar to that of placebo in the two studies. TEAEs occurred in 38 (11.1%) and 41 (11.2%) of Winlevi-treated patients and in 41 (11.7%) and 50 (13.8%) of those who received placebo. No severe or serious TEAEs occurred in any patient treated with Winlevi. The most frequently reported TEAEs were nasophyaryngitis (1.8% and 3.7% for Winlevi, 1.1% and 1.9% for placebo), headache (0.6% and 0.3% for Winlevi, 1.1% and 0.8% for placebo), and oropharyngeal pain (0.6% and 0.3% for Winlevi, 1.1% and 1.1% in both placebo arms). In both studies, the frequencies of each LSR were similar between treatment groups, and the majority of patients did not experience each reaction. The most frequent LSRs were erythema (redness) and scaling/dryness, with the majority of reactions characterized as minimal or mild.

"The data presented at AAD 2022 add to the growing body of evidence supporting the use of Winlevi as a foundational acne treatment," says Nicholas Squittieri, MD, Associate Vice President of Medical Affairs at Sun Pharma, and co-author of the AAD poster presentation, in a news release. "We look forward to further exploring its clinical utility as we conduct more studies and data analyses."

"Before Winlevi became available, there was no topical medication available that was able to reduce sebum production, which is a major cause of acne," adds Hilary Baldwin, MD, Medical Director of the Acne Treatment and Research Center in Brooklyn, NY, and past president of the American Acne and Rosacea Society (AARS). "It is therefore encouraging to see favorable efficacy and safety data results from the latest analysis of the Winlevi Phase 3 clinical trials. This data should also provide dermatologists with confidence that they can use Winlevi to treat both females and males with acne."